Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
Go back to Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026| (NASDAQ: SYRE) | Delayed: 98.51 -1.81 (1.8%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $100.32 | 52 Week High | $ | |||
| Open | $97.72 | 52 Week Low | $ | |||
| Day High | $102.06 | P/E | N/A | |||
| Day Low | $97.14 | EPS | $ | |||
| Volume | 621,904 | |||||
